NASDAQ:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis $1.31 -0.02 (-1.50%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.30 -0.02 (-1.15%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardiol Therapeutics Stock (NASDAQ:CRDL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's Range$1.28▼$1.3650-Day Range$0.93▼$1.6352-Week Range$0.88▼$1.71Volume438,247 shsAverage Volume711,552 shsMarket Capitalization$146.48 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingHold Company Overview Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease. CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes. The company is preparing to initiate further Phase 2 trials in patients with heart failure and preserved ejection fraction to explore the potential of CBD-based therapy to reduce hospitalization rates and improve quality of life. In parallel, Cardiol is investigating novel cyclic dinucleotide immunomodulators designed to recalibrate the innate immune response in cardiovascular settings. Headquartered in Toronto, Canada, Cardiol Therapeutics operates multiple clinical and research collaborations across North America and Europe. Founded in 2017 and rebranded in 2019 after acquiring its core CBD assets, the company is led by Executive Chairman Peter Hamilton, a seasoned life-science executive, alongside a management team with deep expertise in drug development, regulatory affairs, and cardiovascular research. Cardiol’s strategy emphasizes translational science and collaborative clinical programs to address critical unmet needs in heart disease.AI Generated. May Contain Errors. Read More Cardiol Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreCRDL MarketRank™: Cardiol Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 743rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingCardiol Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCardiol Therapeutics has a consensus price target of $8.50, representing about 548.9% upside from its current price of $1.31.Amount of Analyst CoverageCardiol Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cardiol Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cardiol Therapeutics are expected to decrease in the coming year, from ($0.29) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 11.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cardiol Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CRDL. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 3 people have searched for CRDL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows4 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by Institutions12.49% of the stock of Cardiol Therapeutics is held by institutions.Read more about Cardiol Therapeutics' insider trading history. Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRDL Stock News HeadlinesCardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal ProgramApril 28, 2026 | prnewswire.comCardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with BarchartApril 14, 2026 | finanznachrichten.deRevealed: The World’s First Trillion-Dollar RobotJensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar robot. But there's one thing Nvidia can't do alone. A virtually unknown $7 company holds the technology Nvidia needs to make that vision a reality. Analyst Michael Robinson - who called Nvidia at $0.80 and Bitcoin at $300 - has identified this stock as his next potential winner, with nearly 20 prior calls returning 1,000% or more. | Weiss Ratings (Ad)Cardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live InterviewApril 14, 2026 | tipranks.comCardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of ShareholdersApril 10, 2026 | tipranks.comCardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care ConferenceFebruary 25, 2026 | tipranks.comCardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart FailureFebruary 10, 2026 | tipranks.comTop Canadian Stocks to Buy Right Away With $5,000January 21, 2026 | msn.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at $0.9538 on January 1st, 2026. Since then, CRDL stock has increased by 37.3% and is now trading at $1.31. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) issued its quarterly earnings data on Monday, March, 30th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.04. How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings3/30/2026Today5/06/2026Next Earnings (Estimated)5/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CRDL's financial health is in the Green zone, according to TradeSmith. CRDL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDL CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployees20Year Founded2017Price Target and Rating Average Price Target for Cardiol Therapeutics$8.50 High Price Target$9.00 Low Price Target$8.00 Potential Upside/Downside+548.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-239.10% Return on Assets-165.77% Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio4.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book11.91Miscellaneous Outstanding Shares111,820,000Free Float105,947,000Market Cap$146.48 million OptionableNot Optionable Beta0.77 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:CRDL) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredHow to collect $1,170/month from silverThere is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...Investors Alley | SponsoredDid you miss The Dark AI Summit?Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...Brownstone Research | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.When the PC replaced the mainframe, companies that missed the shift went bankrupt. George Gilder - who called ...Eagle Publishing | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
